Format

Send to

Choose Destination
Ann Oncol. 2008 Nov;19(11):1955-61. doi: 10.1093/annonc/mdn389. Epub 2008 Jun 10.

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.

Author information

1
Department of Dermatology, SERIES Clinic, Northwestern University's Feinberg School of Medicine, Chicago, IL 60611, USA. m-lacouture@northwestern.edu

Abstract

BACKGROUND:

This study examined clinicopathological findings and management of hand foot skin reaction (HFSR) to sorafenib and sunitinib in a dermatology referral center for cancer-related toxic effects.

PATIENTS AND METHODS:

We identified 12 patients who developed HFSR in a 1-year period (2007). Medical records and histological specimens were investigated for clinicopathological data and results on management.

RESULTS:

We identified 12 patients developing HFSR on treatment with sorafenib (83%) or sunitinib (17%). Majority presented with grade 3 (75%) HFSR and a median Skindex score of 43. Biopsies in seven patients showed horizontal layers of keratinocyte necrosis, which correlated to time of drug exposure: early (<30 days from initiation) leading to stratum granulosum-spinosum alterations and late (> or =30 days) resulting in stratum corneum pathology. Treatment with topical urea singly (n = 3), plus tazarotene (n = 7), or fluorouracil (n = 2) resulted in > or =2 grade improvement in the majority of patients (58%), with five patients (42%) improving one grade (P = 0.007). Median Skindex score at follow-up was 32 (P = 0.22).

CONCLUSIONS:

There are unique clinicopathological characteristics of HFSR due to the multikinase inhibitors that correlate with time of agent initiation. Treatment with topical agents having keratolytic, antiproliferative, and anti-inflammatory properties showed benefit.

PMID:
18550575
DOI:
10.1093/annonc/mdn389
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center